The B cell response to lymphocytic choriomeningitis virus is characterized by a CD4 + T cell-dependent polyclonal hypergammaglobulinemia and delayed formation of virus-specific neutralizing antibodies. Here we provide evidence that, paradoxically, because of polyclonal B cell activation, virus-specific T cell help impairs the induction of neutralizing antibody responses. Experimental reduction in CD4 + T cell help in vivo resulted in potent neutralizing antibody responses without impairment of CD8 + T cell activity. These unexpected consequences of polyclonal B cell activation may affect vaccine strategies and the treatment of clinically relevant chronic bacterial, parasitic and viral infections in which hypergammaglobulinemia is regularly found.
The B cell response to lymphocytic choriomeningitis virus is characterized by a CD4 + T cell-dependent polyclonal hypergammaglobulinemia and delayed formation of virus-specific neutralizing antibodies. Here we provide evidence that, paradoxically, because of polyclonal B cell activation, virus-specific T cell help impairs the induction of neutralizing antibody responses. Experimental reduction in CD4 + T cell help in vivo resulted in potent neutralizing antibody responses without impairment of CD8 + T cell activity. These unexpected consequences of polyclonal B cell activation may affect vaccine strategies and the treatment of clinically relevant chronic bacterial, parasitic and viral infections in which hypergammaglobulinemia is regularly found.
Lymphocytic choriomeningitis virus (LCMV) is a noncytopathic RNA virus that is initially controlled by a strong CD8 + T cell response in a perforin-dependent way 1, 2 . In contrast, LCMV-neutralizing antibodies usually develop late in infection, after day 50, and remain at low titer 3 . This phenomenon is also found after infection with other poorly cytopathic or noncytopathic viruses such as human immunodeficiency virus (HIV) 4 and hepatitis C virus 5, 6 . Neutralizing antibodies directed against low-cytopathic viruses increase in titer when CD8 + T cell (cytotoxic T lymphocyte (CTL)) function is impaired or absent 3, 7, 8 . Possible mechanisms have been postulated to include CD8 + T cell-dependent immunopathology 9, 10 , enhanced viral replication in the absence of CTLs 2, 8 or the need for affinity or avidity maturation of specific antibodies. These observations also suggest a competitive relationship between cellular and humoral antiviral immune responses, as has been successfully modeled theoretically 11 . LCMV infection induces a strong CD4 + T cell-dependent, virusnonspecific, polyclonal hypergammaglobulinemia 12, 13 , a phenomenon often associated with 'persistence-prone' , low-cytopathic viruses like HIV and hepatitis C virus or with chronic bacterial and parasitic infections. Yet a biological function for polyclonal B cell activation has remained elusive 14 .
Here we have evaluated the function of T helper cells and found that paradoxically, because of polyclonal B cell activation, CD4 + T cells impaired the formation of virus-neutralizing antibodies and favored virus persistence. This inverse causal relationship of T cell help and virus-specific antibody formation was modified only indirectly by CD8 + T cells. Experimental deliberate suppression of T helper responses after LCMV infection resulted in enhanced neutralizing antibody formation while leaving CTL responses intact.
RESULTS

Polyclonal B cell activation versus neutralizing antibodies
Compared with results obtained with control C57BL/6 mice, infection of CD8 + T cell-depleted C57BL/6 or CD8a-deficient (Cd8a À/À ) mice with high-dose (2 Â 10 6 PFU) LCMV, strain WE (LCMV-WE) resulted in increased titers of neutralizing antibodies (Fig. 1a) , correlating with increased viral replication (Fig. 1b) . However, virusinduced polyclonal hypergammaglobulinemia was also modified by CTL function, as both CD8 + T cell-depleted C57BL/6 mice and Cd8a À/À mice showed reduced polyclonal B cell activation early (day 12) after LCMV infection (Fig. 1c) . CD4 + T cells are required for hypergammaglobulinemia 13 . Thus, we examined whether CD4 + T cell function was affected by functional CD8 + T cell depletion. Indeed, CD4 + T cells from CD8 + T cell-depleted or Cd8a À/À mice showed a significant reduction in interferon-g (IFN-g) production after restimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin, compared with that of CD4 + T cells from C57BL/6 mice ( Fig. 1d) . This impaired CD4 + T cell function strictly correlated with the reduced peak in hypergammaglobulinemia in the absence of functional CD8 + T cells (Fig. 1c) , although restimulation by PMA and ionomycin also induces some IFN-g production in naive mice, and absolute virus-specific CD4 + T cell activation may therefore be slightly overestimated. Thus, early polyclonal B cell activation correlated with CD4 + T cell function but was inversely correlated with neutralizing antibody responses.
Impairment of neutralizing antibody responses by CD4 + T cells
To analyze whether the stated inverse relationship was due to a direct suppressive effect of virus-specific T cell help on neutralizing antibody formation, we infected mice with LCMV-WE in the presence or absence of adoptively transferred LCMV-specific CD4 + T helper cells. We obtained these CD4 + cells from Smarta1 mice, which carry a transgenic T cell receptor specific for the LCMV T helper epitope consisting of glycoprotein amino acids 61-80 (GP(61-80)) 15 . We examined Cd8a À/À mice as recipients to exclude the possibility of a direct effect of T helper cells on CTL function. LCMV-infected Cd8a À/À mice that did not receive Smarta1 splenocytes developed a strong neutralizing antibody response ( Fig. 2a and ref. 7 ). This result correlated with a transient reduction (499%) in blood virus titers ( Fig. 2b and ref. 7) . In contrast, Cd8a À/À mice that received cells from Smarta1 mice failed to mount measurable neutralizing activity (Fig. 2a) , and blood virus titers remained consistently high (Fig. 2b) . This indicated that the addition of virus-specific CD4 + T cell help inhibited the production of neutralizing antibodies. As expected, hypergammaglobulinemia was increased in the presence of additional virus-specific T cell help (Fig. 2c) .
Next, we examined if the reduction in virus-specific T cell help was followed by enhanced neutralizing antibody formation. These experiments profited from knowledge of two characterized immunodominant LCMV-derived major histocompatibility complex (MHC) class II epitopes, the aforementioned GP(61-80) and nucleoprotein-derived NP(309-327) 16, 17 , which account for most of the LCMV-specific CD4 + T cell response 18 . We took advantage of a newly isolated LCMV variant, LCMV-WE del (ref. 19) , which contains an eightamino acid deletion at positions 61-68 of the LCMV glycoprotein, spanning the immunodominant MHC class II H-2 b epitope GP(61-80) (ref. 16, 17 ; Table 1 ). This epitope is recognized by Smarta1 T helper cells. Infection of Cd8a À/À mice with LCMV-WE del induced an early and strong neutralizing antibody response (Fig. 2a) . This response was not altered by the presence of CD4 + T cells from Smarta1 mice (Fig. 2a) . This indicated that the inhibition of the neutralizing antibody response by virus-specific CD4 + T cells occurred in an epitope-specific way. Consistent with the early induction of neutralizing antibodies, Cd8a À/À mice infected with LCMV-WE del showed rapid clearance of virus from peripheral blood ( Fig. 2b) and had only moderate hypergammaglobulinemia ( Supplementary  Fig. 1 online) . These experiments demonstrated a causal, inverse correlation of CD4 + T cell-dependent polyclonal B cell activation and neutralizing antibody responses. In addition, virus dosage influenced the degree of functional CD4 + T cell anergy in the absence of CTLs. Infection of Cd8a À/À mice with low virus doses (for example, 200 PFU LCMV-WE) was followed by robust IFN-g production by virus-specific CD4 + T cells, whereas high virus doses (2 Â 10 6 PFU LCMV-WE) led to impaired CD4 + T cell function ( Supplementary  Fig. 1 online) . Accordingly, polyclonal B cell activation was suppressed and neutralizing antibodies were high after high-dose LCMV-WE infection, whereas hypergammaglobulinemia was enhanced and neutralizing antibody titers were low after low-dose LCMV-WE infection ( Supplementary Fig. 1 online) . Low-dose (200 PFU) LCMV-WE del induced only minimal polyclonal B cell activation in Cd8a À/À mice. Again, the decreased hypergammaglobulinemia found after LCMV-WE del infection correlated inversely with neutralizing antibody production ( Supplementary Fig. 1 online) .
Antibody formation in CD8 + T cell-competent mice Our data have provided evidence that virus-specific CD4 + T cells may directly negatively influence neutralizing antibody formation. In (Fig. 3a) . In contrast, restimulation of the same splenocytes with the NP(309-327) MHC class II peptide produced comparable IFN-g production (Fig. 3a) . To determine the function of subdominant epitopes, we infected C57BL/6 mice with 200 PFU LCMV-WE or 200 PFU LCMV-WE del and restimulated splenocytes polyclonally with PMA and ionomycin. We detected approximately half the percentage of IFN-g producing CD4 + T cells in mice infected with LCMV-WE del compared with that in mice infected with LCMV-WE (Fig. 3a) . Thus, the loss of the immunodominant MHC class II epitope resulted in weakened CD4 + T cell responses.
To further confirm that LCMV-WE del had a complete absence of the GP(61-80) epitope in vivo, we infected Smarta1 mice with 200 PFU LCMV-WE or LCMV-WE del . Whereas infection with LCMV-WE induced a notable downregulation of the activation marker CD62L on Smarta1 CD4 + T cells at day 5 after infection, we found no indication of Smarta1 T cell activation after infection with LCMV-WE del (Fig. 3b) . As noted for CD8 + T cell-deficient mice, low-dose infection (200 PFU) of wild-type C57BL/6 mice with LCMV-WE del resulted in enhanced neutralizing antibody titers compared with LCMV-WE infection. Neutralizing serum activity became detectable by day 30 and remained increased until at least day 200 (Fig. 3c) , whereas neutralizing antibodies remained low after LCMV-WE infection. Sera from LCMV-WE del -infected mice neutralized both LCMV-WE del and wild-type LCMV-WE virus in vitro, whereas sera from LCMV-WEinfected mice could not neutralize either virus. These data indicated that the glycoprotein structure was conserved in both viruses and was equally accessible to neutralizing antibodies (Fig. 3c ). This conclusion was supported by the comparable neutralization of LCMV-WE del and LCMV-WE in vitro by the monoclonal LCMV-WE-neutralizing antibody KL25 (ref. 20 ; Fig. 3d ). LCMV glycoprotein-specific enzymelinked immunosorbent assay (ELISA) IgG antibodies were also enhanced after infection with LCMV-WE del compared with antibodies present after infection with LCMV-WE (Fig. 3e) . These ELISA IgG titers were induced early after infection (days [12] [13] [14] [15] [16] [17] [18] [19] [20] , in contrast to neutralizing antibodies, which appeared after days 30-40 ( Fig. 3c) . In contrast, early total serum immunoglobulin concentrations (which represent mainly IgG isotypes 13 ) were decreased in LCMV-WE delinfected mice compared with LCMV-WE-infected mice (Fig. 3f) . These results indicated that an intermediate amount of CD4 + T cell help reduced polyclonal B cell activation and was associated with increased virus-specific IgG formation.
To rule out the possibility that a dominant function of the LCMV-WE del glycoprotein was itself responsible for enhanced neutralizing antibody responses, we co-infected C57BL/6 mice with 200 PFU LCMV-WE del and LCMV-WE. After co-infection, virus-specific IgG production was very low (Fig. 3e ) and was associated with an enhanced hypergammaglobulinemia compared with that after infection with LCMV-WE del alone (Fig. 3f) . This result suggested that infection with LCMV-WE del did not mediate an increased production of virus-specific antibodies itself, but that this increase was a result of the reduced polyclonal B cell activation. We next examined whether the different titers of LCMV-neutralizing antibodies found after infection with LCMV-WE or LCMV-WE del resulted in different protective capacities against a challenge infection. We collected and pooled sera from mice given primary infection with 200 PFU LCMV-WE or LCMV-WE del (days 40-80 after infection) and transferred this sera into naive C57BL/6 mice, which we then challenged intravenously with 200 PFU LCMV-WE. We also used control C57BL/6 mice that did not receive serum and infected them with LCMV-WE. On day 4 after challenge infection, virus titers in spleens in mice that had received serum from LCMV-WE del -infected mice were 0.1% those of mice that received the same volume of serum from LCMV-WEinfected mice (Fig. 3g) . Transfer of serum from LCMV-WE mice mediated only minor protection compared with that of control mice that had not received LCMV-immune serum (Fig. 3g) .
Effects of partial CD4 + T cell depletion
The hypothesis that CD4 + T cell help may inhibit the formation of virus-neutralizing antibodies through the promotion of polyclonal B cell activation 'predicts' that experimental reduction but not complete elimination of functional T cell help should result in enhanced virus-specific antibody titers after wild-type LCMV-WE infection. We treated mice with titrated doses of the CD4 + T celldepleting monoclonal antibody YTS191.6 (ref. 21 ) before infecting the mice with 200 PFU LCMV-WE on day 0. The normal protocol of CD4 + T cell depletion with two injections of YTS191.6, on days À3 and À1, resulted in complete disappearance of CD4 + T cells from the blood up to day 12, as assessed by flow cytometry (Fig. 4a) Serum immunoglobulins (% of total serum protein) a b c Figure 2 Inverse correlation between virus-specific T cell help and neutralizing antibody responses in Cd8a À/À mice. Cd8a À/À mice were infected with 5 Â 10 3 PFU LCMV-WE (WE) or LCMV-WE del (WE del ). The mice also received 1 Â 10 7 Smarta1 splenocytes intravenously on the day of infection ( + Smarta1) or were left untreated (times, horizontal axes). (a) Analysis of sera by neutralization assay against LCMV-WE. (b) Virus plaque assay of blood viral titers. (c) Analysis of total serum immunoglobulins by serum electrophoresis. Five individual mice were tested on day 12 after infection. Pooled serum of two to three mice was analyzed at days 20 and 30. Data are expressed as mean 7 s.e.m. of three to five mice per group except in b, for which data from three individual mice are presented. All data are representative of two separate experiments (total n ¼ 5-8).
9 3 6 VOLUME 5 NUMBER 9 SEPTEMBER 2004 NATURE IMMUNOLOGY associated with an absence of serum hypergammaglobulinemia (Fig. 3f) . In contrast, treatment with a 1:100 dilution of the depleting antibody had a transient effect, such that CD4 + T cells were initially depleted but had already regained normal numbers by day 12 after infection ( Fig. 4a) . Such transient and partial CD4 + T cell depletion led to the development of increased LCMV-specific IgG antibody titers (Fig. 4b) . As expected, complete depletion of CD4 + T cells resulted in a failure to produce LCMV-specific IgG antibodies (Fig. 4b) . The positive effect of partial CD4 + T cell depletion on the production of neutralizing antibodies was similarly demonstrated in CD8 + T cell-deficient mice, which had already cleared the LCMV-WE infection from the peripheral blood by day 20 (Fig.  4c,d) . Thus, the partial depletion of CD4 + T cells provided another line of evidence supporting the proposal that limited T cell help results in the formation of an accelerated and improved neutralizing antibody response.
Coexistence of neutralizing antibody and CTL responses
Early CD4 + T cell help is important in the generation of CD8 + T cell memory [21] [22] [23] . Whereas the initial clonal burst and early CD8 + T cell function is mostly CD4 + T cell independent, memory CD8 + T cell responses apparently require CD4 + T cell help. Thus, the potential therapeutic use of virus variants lacking immunodominant MHC class II epitopes or partial CD4 + T cell depletion in vivo may become a 'double-edged sword' . That is, enhanced neutralizing antibodies would have to compensate for a potentially impaired CTL memory response. We therefore examined acute and memory CTL responses induced by infection with LCMV-WE (with or without partial CD4 + T cell depletion) or LCMV-WE del . At early time points after infection (day 8), we found no significant differences in either LCMV-specific tetramer-positive CD8 + T cell numbers (data not shown) or IFN-g production after short-term (6 h) in vitro re-stimulation with MHC class I peptides derived from LCMV glycoprotein (GP (33) (34) (35) (36) (37) (38) (39) (40) (41) or GP(276-284)) or LCMV nucleoprotein (NP(396-404); Fig. 5a ). Numbers of tetramer-positive memory CD8 + T cells from mice infected with LCMV-WE (with or without partial CD4 + T cell depletion) or LCMV-WE del were also comparable at day 120 after infection (Fig. 5b,c) . To test the functional capacity of these CD8 + T cells, we partially depleted C57BL/6 mice of T helper cells and challenged these and nondepleted control mice, 130 days after infection with 200 PFU LCMV-WE, with CFSE-labeled splenocytes pulsed with the LCMV GP (33) (34) (35) (36) (37) (38) (39) (40) (41) eliminated 65.6% 7 4.97% of the peptide-pulsed cells, whereas LCMV-WE-infected control C57BL/6 mice showed a slightly reduced cytotoxicity in vivo (38.9% 7 2.54%; Fig. 5d ). These experiments indicated that potent neutralizing antibody and CD8 + T cell responses could potentially coexist in vivo and that partial depletion of CD4 + T cells did not obviously impair CTL memory responses in our test conditions.
Influence of virus replication on antibody responses
The idea that T helper cell-dependent polyclonal B cell activation can impair production of virus-neutralizing antibodies was supported by experiments in both immunocompetent and CD8 + T cell-deficient mice. Nevertheless, neutralizing antibody responses were usually shifted toward higher titers in experiments in which CD8 + T cells were absent. This suggested an additional function for virus replication in the formation of neutralizing antibody responses. To directly determine this influence, we examined mice deficient for type I and type II interferon receptors (AGR mice), in which virus replication is enhanced [24] [25] [26] [27] . Low-dose (200 PFU) LCMV-WE infection of AGR mice resulted in the development of an 'LCMV carrier status' . We did not detect neutralizing antibodies in AGR mice infected with LCMV-WE (Fig. 6a) , despite the presence of high-titer virus replication (Fig. 6b) . In contrast, infection of AGR-mice with 200 PFU LCMV-WE del resulted in sera that were able to neutralize sera even when diluted 1,000-fold. This neutralizing antibody response occurred in the presence of viral antigen concentrations that were comparable to those seen after wild-type LCMV-WE infection (Fig. 6b, days 8-20) . However, by day 25 after infection, the appearance of neutralizing antibodies in mice infected with LCMV-WE del coincided with As noted for CD8 + T cell-deficient mice, neutralizing antibody 'escape variants' eventually arose and could be detected in the blood at late time points (4day 80; Fig. 6b ).
LCMV-WE infection of AGR mice resulted in a sharp increase in total serum immunoglobulin concentrations (Fig. 6c) , detectable by day 10 after infection and occurring in parallel with a massive downregulation of the activation marker CD62L on blood CD4 + T cells (Fig. 6d) . In contrast, only moderate hypergammaglobulinemia was measured in AGR mice infected with LCMV-WE del (Fig. 6c) , associated with reduced CD4 + T cell activation (Fig. 6d) . Thus, here the induction of the neutralizing antibody response occurred independently of high viral load (apparent in mice lacking interferon receptors), but yet again correlated with reduced CD4 + T celldependent early hypergammaglobulinemia. These experiments also indicated that a combination of high virus replication and limited early polyclonal B cell activation resulted in enhanced neutralizing antibody responses.
Virus-specific and nonspecific B cell competition To elucidate the mechanisms by which CD4 + T cell-dependent hypergammaglobulinemia impaired production of LCMV-specific neutralizing antibodies, we investigated whether this effect was limited to LCMV antigens or whether antibody responses to LCMV-unrelated antigens were also affected 30 (Fig. 7) . We examined whether LCMVinduced polyclonal B cell activation correlated with decreased neutralizing antibody responses against vesicular stomatitis virus (VSV) after co-infection with both viruses. We infected C57BL/6 mice with 2 Â 10 6 PFU VSV 6 d after LCMV-WE infection and determined the formation of neutralizing antibodies to VSV. We used this infection schedule Figure 6 The efficiency of the neutralizing antibody response can be predicted largely by the extent of polyclonal B cell activation but is also modified by the extent of virus replication. so that the peak of LCMV-induced hypergammaglobulinemia (day 12) would coincide with the time of IgG isotype switching in response to VSV infection (day 6). In C57BL/6 mice preinfected with LCMV-WE, we noted a reduction in neutralizing IgG antibodies to VSV (anti-VSV IgG) compared with that of control mice infected with VSV alone (Fig. 7a) . This effect was also apparent in CD8 + T cell-depleted or Cd8a À/À mice (Fig. 7a) , indicating that LCMV-induced CD8 + T cell-mediated immunopathology was not (or was not solely) responsible for the effect on neutralizing antibody responses noted. Although polyclonal B cell activation was reduced in CD8 + T cell-deficient mice (Fig. 7c) , it was obviously sufficient to suppress VSV-specific IgG production (Fig. 7a) . In contrast, early neutralizing IgM antibodies to VSV were increased in mice co-infected with LCMV and VSV (Fig. 7b) . Thus, LCMV-induced polyclonal B cell activation (Fig. 7c) was also able to inhibit IgG isotype switching of B cells 'encoding' antibodies specific for VSV. We next examined whether the LCMV-induced polyclonal B cell competition could be compensated by the presence of increased VSV-specific B cell precursor frequencies. We adoptively transferred splenocytes from a transgenic mouse expressing a 'switchable' neutralizing anti-VSV B cell receptor, VI10Yen 28 , into naive C57BL/6 mice. We then infected recipient mice with 2 Â 10 6 PFU LCMV-WE and coinfected the mice 6 d later with 2 Â 10 6 PFU VSV, as described above. Inhibition of neutralizing anti-VSV IgG by LCMV coinfection was reversed by increased numbers of VI10Yen B cells in a dose-dependent way (Fig. 7d) . This indicated that the inhibition was effective only at low B cell precursor frequencies. To confirm this finding with another experimental approach, we analyzed the ability of LCMVinduced polyclonal B cell activation to 'compete out' IgG responses specific for (2,4-dinitrophenyl)-albumin (DNP-albumin). High B cell precursor frequencies exist against DNP-albumin hapten carrier conjugates in naive C57BL/6 mice 29 . Anti-DNP-albumin IgG titers were not impaired but were even increased by LCMV preinfection, reflecting the polyclonal B cell stimulation (Fig. 7e) . Thus, we noted the competitive effect of LCMV-induced polyclonal B cell activation against LCMV-related and LCMV-unrelated specificities, however, only if precursor frequencies of the relevant B cells were relatively low.
DISCUSSION
Delayed neutralizing antibody responses after infection with a persistent virus was, in our experiments, directly correlated with the activation kinetics and functional responsiveness of virus-specific CD4 + T cells. A reduction in CD4 + T cell function and/or reduction in CD4 + T cell numbers reduced polyclonal B cell stimulation, apparently by 'concentration' of specific T cell help onto virus-specific B cells. In contrast, strong (and even normal) virus-specific CD4 + T cell activation resulted in heightened early polyclonal B cell activation, which competed with virus-specific B cell activation and the formation of neutralizing antibodies. An absence of CD8 + T cells indirectly affected neutralizing antibody production by enhancing virus replication, which in turn favored CD4 + T cell anergy or unresponsiveness. The inverse correlation between early hypergammaglobulinemia and neutralizing antibody responses affected also LCMV-unrelated protective antibody responses (for example, against VSV). This competition for antigen-specific B cells was seen only for B cells with physiologically low precursor frequencies.
Our experiments here cannot determine whether this biological consequences of polyclonal B cell activation results from a competition for B cell survival factors or for 'anatomical niches' that promote B cell isotype switching by rendering cognate CD4 + T cell-B cell interactions more or less efficient. Should the competition involve anatomical structures, then CD8 + T cell-induced immunopathological disruption of lymphoid tissue organization may further enhance this effect 9, 10 . Additionally, increased virus replication may influence the kinetics of avidity and/or affinity maturation of virus-specific antibodies. The evidence presented here suggests that the latter effects are additional or secondary to the influence of polyclonal B cell activation.
Whereas high-affinity neutralizing antibodies are key effector mechanisms against acutely cytopathic virus infections, such as rabies (or VSV) and poliovirus 31 , infections with poorly cytopathic or noncytopathic viruses, including LCMV, hepatitis C virus or HIV, typically result in delayed formation of protective neutralizing antibodies 3, 31, 32 . Instead, in these latter infections, virus replication is initially controlled by strong, although often transient, CD8 + T cell responses 33 . For persistent virus-host interactions, a competitive coexistence of humoral and cellular immunity has been described experimentally 8 and theoretically 11 ; thus, neutralizing antibodies may act as an additional line of defense when CD8 + T cell responses become weakened. This competitive coexistence may be beneficial to the host by averting a combination of strong cytotoxicity and antibody responses that may favor immunopathology and autoimmune manifestations. However, virus persistence after HIV or LCMV infection could be substantially reduced if both CTLs and neutralizing antibodies were experimentally available at early time points after infection by exogenous addition 34, 35 . In addition, the combination of neutralizing antibodies and CD8 + T cells should suppress the risk of either CTL or neutralizing antibody escape variant formation 7, 36 . We believe that coevolution of such noncytopathic or low cytopathic viruses and mammalian hosts has yielded mechanisms that avoid production of potent neutralizing antibody responses, thereby favoring virus persistence. With overwhelming virus infections such as LCMV, virus may persist not only as a result of CD8 + T cell deletion and/or exhaustion but also as a consequence of increased polyclonal B cell activation 37 .
Given the demonstration that CD8 + T cells impair the formation of neutralizing antibodies partially indirectly by induction of CD4 + T cell anergy, it might be difficult but not impossible to induce both a protective CTL and an accelerated neutralizing antibody response. In fact, we have demonstrated here that a reduction in CD4 + T cell function early during LCMV infection can decrease polyclonal B cell activation and thus can improve neutralizing antibody responses in immunocompetent hosts while leaving CTL responses intact.
What may be learned from the LCMV model infections presented here to better elucidate of HIV pathogenesis? High HIV viremia can be associated with an anergic state of virus-specific CD4 + T cells 38 . Antiviral therapy reduces HIV-induced polyclonal hypergammaglobulinemia 39 and in parallel increases neutralizing antibody responses against autologous virus 40 . These results are all consistent with our findings with LCMV. In addition, early hyperactivity of CD4 + T cells represents an independent risk factor for disease progression after HIV infection 41 T cell function, disruption of lymphatic architecture or glycan shields that conceal the neutralizing epitope on the HIV glycoprotein 43, 44 . Our experiments may suggest potential strategies for experimentally and therapeutically influencing persistent virus infections by reducing virus-induced polyclonal B cell activation and thereby enhancing neutralizing antibody production. The deliberate impairment of T cell help during immunization either by the use of vaccines with mutated or deleted CD4 + T cell epitopes or, alternatively, by partial depletion of CD4 + T cell function in vivo, although counterintuitive and probably difficult to control, may be worth careful consideration.
METHODS
Mice. All mice were bred and maintained in specific pathogen-free conditions and experiments were done in accordance with institutional and Swiss guidelines. Cd8a À/À , VI10Yen and Smarta1 mice were all on a C57BL/6 (H-2 b ) background. AG129 mice were on a 129/Sv (H-2 b ) background. All mice were obtained from the Institute for Labortierkunde, Faculty of Veterinary Medicine, University Zürich-Irchel, Switzerland.
Virus. The LCMV strain WE was originally obtained from F. Lehmann-Grube (Heinrich Pette Institute, Hamburg, Germany) and was propagated on L929 and/or MC57 cells. Mice were infected intravenously with 2 Â 10 2 PFU (low dose), 5 Â 10 3 PFU (intermediate dose) or 2 Â 10 6 PFU (high dose) LCMV-WE. LCMV-WE del was previously isolated from LCMV-WE-infected DBA/2 mice 19 . VSV-Indiana (VSV-IND) and VSV-New Jersey (VSV-NJ) were originally obtained from D.Kolakofsky (University of Geneva, Switzerland) and were grown on BHK cells. Mice were infected intravenously.
Sequencing. The cDNA encoding LCMV-WE del glycoprotein was sequenced as described 19 .
Detection of virus and neutralizing antibody titers. LCMV virus titers were determined by plaque-forming assay on MC57 fibroblasts as described 45 . Detection of neutralizing activity against LCMV in mouse sera has been described 45 . Neutralizing activity against LCMV-WE or LCMV-WE del was measured by plaque-reduction assay. The neutralizing titer was defined as the log 2 dilution resulting in half-maximal reduction of plaques compared with the same amount of virus incubated with control sera from uninfected mice or medium alone. A titer of less than 1 indicates no detectable neutralization of a 1:10 predilution of serum incubated with an equal volume of virus for 90 min before addition of the mixture to MC57 fibroblasts. Neutralizing total (IgM plus IgG) and IgG antibodies to VSV were measured as described 46 .
In vivo depletion of CD4 + and CD8 + T cells. Depletion of cells used rat monoclonal antibodies specific for CD4 (YTS 191.6) or CD8 (YTS 169.4) as described 20 and were provided by H. Waldmann (Therapeutic Immunology Group, Oxford, UK). Antibody (200 ml) was injected intraperitoneally on days À3 and À1 (before infection at day 0). For partial CD4 + T cell depletion, 200 ml of a 1:100 dilution (in PBS) was injected intraperitoneally on day À1. The efficiency of depletion was confirmed by flow cytometry of peripheral blood cells with fluorescein isothiocyanate-or phycoerythrin-labeled anti-CD4 or anti-CD8 (BD Pharmingen).
Serum protein electrophoresis to quantify hypergammaglobulinemia. Detection of serum immunoglobulin as a function of total serum protein was done by the Department of Clinical Chemistry, University Hospital, Zürich, Switzerland. Serum was separated by agarose gel electrophoresis (Sebia) and the fractions were quantified with a densitometer (Beckmann Coulter).
LCMV-specific tetramers. Tetramers specific for LCMV glycoprotein (GP (33) (34) (35) (36) (37) (38) (39) (40) (41) and GP(276-284)) and nucleoprotein (NP(396-404)) have been described 47 . Phycoerythrin-labeled tetramers were used.
Intracellular cytokine staining for IFN-c and flow cytometry. Splenocytes were re-stimulated overnight with baculovirus-derived recombinant LCMV nucleoprotein in RPMI medium supplemented with FCS (10% final concentration) and b-mercaptoethanol (0.1 mM final concentration). For T cell restimulation, cells were cultured for 6 h in medium containing phorbol 12-myristate 13-acetate (PMA; 50 ng/ml) and ionomycin (500 ng/ml) or alternatively one of the following peptides (at a concentration of 50 mg/ml): GP(61-80), GP (33) (34) (35) (36) (37) (38) (39) (40) (41) and GP(276-286) or NP(309-328) and NP(396-404). Brefeldin A (10 mg/ml; Sigma-Aldrich) was added for the last 5 h of culture. Cells were then collected, washed once in PBS with 4% FCS and 12.5 mM EDTA and stained with phycoerythrin-conjugated anti-CD4 or anti-CD8 (BD Pharmingen). After being washed, cells were fixed with 4% paraformaldehyde (in PBS) for 10 min, then were permeabilized with PBS containing 4% FCS, 12.5 mM EDTA and 0.1% saponin (Sigma-Aldrich). For intracellular cytokine staining, cells were incubated for 45 min at 4 1C with fluorescein isothiocyanate-or allophycocyanin-conjugated anti-IFN-g (BD PharMingen). After being washed twice with permeabilization buffer, cells were resuspended in PBS containing 4% FCS and 12.5 mM EDTA and were analyzed with a FACScan or FACSCalibur (BD).
Examination of CD4 + T cell activation. Expression of the selectin CD62L on blood CD4 + T cells was examined by staining with anti-mouse CD4-fluorescein isothiocyanate and anti-mouse CD62L-phycoerythrin (both from BD Pharmingen), followed by analysis with a FACSCalibur (BD).
In vivo cytotoxicity. Assays for in vivo cytotoxicity were done with C57BL/6 splenocytes incubated for 1 h with or without LCMV-derived MHC class I GP(33-41) peptide and labeled for 10 min with carboxyfluorescein diacetate succinimidyl diester (CFSE) at a concentration of 5 mg/ml (CFSE hi , peptidelabeled splenocytes) or 0.5 mg/ml (CFSE lo , splenocytes not labeled with peptide; Molecular Probes). 'LCMV memory' or naive control mice were injected intravenously with 1 Â 10 7 cells of each fraction. The number of CFSE + cells remaining in the blood after 4 h was determined by flow cytometry. Specific cytotoxicity was calculated with the following equation: cytotoxicity (%) ¼ 1 -[(CFSE hi (memory)/CFSE lo (memory))/(CFSE hi (naive)/CFSE lo (naive))].
ELISA. For analysis of LCMV glycoprotein, 96-well plates were coated with 100 ml recombinant LCMV glycoprotein supernatant derived from HEK293 cells transfected with LCMV glycoprotein vector. Sera prediluted 1:30 were incubated for 90 min, washed with PBS containing 0.5% Tween 20, then incubated further with anti-mouse IgG-horseradish peroxidase (1:1,000 dilution; Sigma-Aldrich) for detection of virus-specific IgG responses. For the detection of IgG antibodies specific for DNP-albumin conjugate, plates were coated overnight with 10 mg/ml of DNP-serum albumin (Sigma-Aldrich). Plates were then blocked for 2 h at 25 1C with 2% BSA in PBS. Sera prediluted 1:30 were incubated for 90 min. Anti-mouse IgG-horseradish peroxidase (1:1,000 dilution; Sigma-Aldrich) was used to detect specific IgG responses. In all ELISAs, a green color reaction was produced with 2,2¢-azino-bis (3-ethylbenzothiazoline-6-sulfonate) as a substrate (ABTS; Boehringer-Mannheim). The ELISA titer was defined as the log 2 serum dilution resulting in an optical density at 450 nm twofold above background.
KL25 plaque-neutralization assay. For these assays, 30-50 PFU LCMV-WE or LCMV-WE del were incubated in 96-well plates for 90 min with twofold dilutions (starting at 0.5 mg/ml) of the LCMV-neutralizing monoclonal antibody KL25 (ref. 20) . Plaques were then evaluated on MC57 fibroblasts as described 45 . Foci were counted in triplicate and the percentage of plaque formation in the absence of KL25 (considered 100% PFU) was calculated and plotted against (log 2 ) KL25 dilution.
Serum transfer. For measurement of the protective antibody capacity against a challenge LCMV infection, 100 ml of pooled serum after LCMV-WE or LCMV-WE del infection of C57BL/6 mice (40-80 d after infection) was adoptively transferred intravenously into naive C57BL/6 mice. The mice were challenged 2 h later with 200 PFU LCMV-WE and spleen virus titers were measured 4 d later by plaque assay.
Statistical analysis. Data are expressed as mean and s.e.m. Where indicated, significance was assessed with the paired t-test. P values above 0.05 were considered not significant.
